Skip to main content

Table 2 Characteristics of the study subjects

From: First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

Study group Subject ID Age/sex/race Infected HIV-1 subtype Days of cART prior to entry CD3 +/CD4 + level at entry (cells/µl) Plasma HIV-1 RNA level at entry (copies/ml)
SAV001 2001004 43/male/black B 537 1826 <2.00E+1
1001005 37/male/white ND 443 570 <2.00E+1
2001008 40/male/white B 1380 830 <2.00E+1
2001009 28/male/white A 960 500 <2.00E+1d
2001012 27/male/white B 1832 598 <2.00E+1
3001015 35/male/white B 1185c 694 2.50E+1
3001018 44/male/white B 1430 804 <2.00E+1
2001022 30/male/white B 229 419 <2.00E+1
3001024 50/male/white B 1097 486 2.22E+1
1001025 44/female/white B 2478 574 <2.00E+1
4001029 30/male/black B 445 491 <2.00E+1
3001032 46/female/othera ND 1885c 440 <2.00E+1
3001033 45/male/white B 395c 515 <2.00E+1
Placebo 2001002 25/male/white B 1011 702 <2.00E+1
2001013 46/male/white ND 573 618 <2.00E+1
1001020 48/male/white B 1843 754 <2.00E+1
3001027 25/male/white B 265 366 <2.00E+1
SAV001 + adjuvant 1001001 46/male/white B 1269 539 <2.00E+1
1001003 49/male/white A 1289 833 <2.00E+1
2001006 21/male/white B 333 581 <2.00E+1
2001010 46/male/white B 4745c 739 <2.00E+1
2001011 33/female/black B 1559 369 <2.00E+1
3001016 48/male/white B 730c 626 <2.00E+1
3001017 43/male/white B 1550 459 <2.00E+1
3001019 35/male/Asian A 2220c 555 <2.00E+1
2001021 49/male/white B 1848 1079 <2.00E+1
3001026 29/male/white C 252 485 <2.00E+1
4001028 41/male/black A 637 449 <2.00E+1
4001031 40/male/white ND 1290 794 <2.00E+1
Placebo +adjuv. 1001014 47/male/white B 970c 827 <2.00E+1
2001007 48/male/asian D 638 498 <2.00E+1
1001023 49/male/white B 1316 1057 <2.00E+1
4001030 25/female/otherb B 448 519 <2.00E+1
  1. ND not done
  2. aNative American and black
  3. bMexican
  4. cApproximate days
  5. dEvaluated at screening day